Skip to content
Research Article Open access CC BY 3.0

Aldose Reductase Inhibitors for Diabetic Cataract: A Study of Disclosure Patterns in Patents and Peer Review Papers

H. A. M. Mucke, E. Mucke, P. M. Mucke

Ophthalmology Research: An International Journal · pp. 137–149 · Published 15 Jan 2014

10.9734/OR/2014/7224

Abstract

Aims: To investigate, for 13 aldose reductase inhibitors that had been in development for diabetic cataract, whether patent documents could provide earlier dissemination of knowledge to the ophthalmology community than peer review papers. Methodology: Searches for intellectual property disclosures were conducted in our internal database of ophthalmology patent documents, and were supplemented by online searches in the public Espacenet and Google Patents databases. Searches for peer review papers were performed in Pub Med and Google Scholar, and in our internal database of machine-readable ophthalmology publications. Results: For sorbinil, tolrestat, fidarestat and GP-1447 patent documents clearly preempted the peer review literature in terms of data-supported information on potential effectiveness in diabetic cataract, typically by 7-17 months. For alrestatin, zenarestat, zopolrestat, indomethacin, and quercitrin academic journals were clearly first to properly report this therapeutic utility, preempting the corresponding patents by 6 months to several years. For ponalrestat, risarestat, epalrestat, and lidorestat claims of utility in diabetic cataract were first made in patent documents, but with insufficient or incomplete support. Conclusion: Our results suggest that including patent documents in the routine monitoring of newly disclosed knowledge could significantly improve the comprehensiveness of the literature base in ocular pharmacology, and has the potential to alert researchers to emerging drug candidates earlier than reports in the peer review literature.  

Cataract diabetes complications diabetes mellitus experimental aldose reductase patents as topic peer review databases, bibliographic information storage and retrieval

References (26)

  1. 1 Isolation and Properties of Lens Aldose Reductase [DOI]
  2. 2 Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]-1-phthalazineacetic acid (zopolrestat) and congeners [DOI]
  3. 3 Discovery of 3-[(4,5,7-Trifluorobenzothiazol-2-yl)methyl]indole-N-acetic Acid (Lidorestat) and Congeners as Highly Potent and Selective Inhibitors of Aldose Reductase for Treatment of Chronic Diabetic Complications [DOI]
  4. 4 Formation of Polyols by the Lens of the Rat with ‘Sugar’ Cataract [DOI]
  5. 5 Polyol Accumulation in Galactosemic and Diabetic Rats: Control by an Aldose Reductase Inhibitor [DOI]
  6. 6 Aldose reductase in diabetic complications of the eye [DOI]
  7. 7 Diabetic Cataracts and Flavonoids [DOI]
  8. 8 Flavonoids as Inhibitors of Lens Aldose Reductase [DOI]
  9. 9 Effects of a new aldose reductase inhibitor on various tissues in vitro. [DOI]
  10. 10 N-[[5-(Trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]-N-methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor [DOI]
  11. 11 Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat [DOI]
  12. 12 The effect of an aldose reductase inhibitor on the galactose-exposed rabbit lens [DOI]
  13. 13 Cataract Formation through the Polyol Pathway is associated with Free Radical Production [DOI]
  14. 14 A randomised, placebo controlled clinical trial of the aldose reductase inhibitor CT-112 as management of corneal epithelial disorders in diabetic patients [DOI]
  15. 15 Biomedicine & aging pathology
  16. 16 Effects of a Novel Potent Aldose Reductase Inhibitor, GP-1447, on Aldose Reductase Activity In Vitro and on Diabetic Neuropathy and Cataract Formation in Rats [DOI]
  17. 17 Pharmacological Therapies for Cataract and Refractive Errors: Landscaping Niches of Ocular Drug Patenting [DOI]
  18. 18 CP-45,634: A novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats [DOI]
  19. 19 The failure of aldose reductase inhibitor 3,3′-tetramethylene glutaric acid to inhibit in vivo sorbitol accumulation in lens and retina in diabetes [DOI]
  20. 20 Inhibition of lens and cataract aldose reductase by protein-bound anti-rheumatic drugs: Salicylate, indomethacin, oxyphenbutazone, sulindac [DOI]
  21. 21 Prevention of Cataract Development in Severely Galactosemic Rats by the Aldose Reductase Inhibitor, Tolrestat [DOI]
  22. 22 Studies on antidiabetic agents. III. 5-Arylthiazolidine-2,4-diones as potent aldose reductase inhibitors. [DOI]
  23. 23 Effects of aldose reductase inhibitor, CT-112, on sugar alcohol accumulation in corneal epithelium of galactose-fed rats.
  24. 24 [Preventional and therapeutic effects of aldose reductase inhibitor FR74366 on rat galactose cataract].
  25. 25 Quercitrin gallate inhibits aldose reductase activity and xylose-induced lens opacity and oxidation [DOI]
  26. 26 Towards the Ophthalmology Patentome: a Comprehensive Patent Database of Ocular Drugs and Biomarkers [DOI]

Cited by 7

Utilization of carbon dioxide as a building block in synthesis of active pharmaceutical ingredients

Muhammad Faisal · Green Sustainable Process for Chemical and Environmental Engineering and Science · 2023

The protective effect of pomegranate peel aqueous extract on selenite‐induced cataract in rats

Arash Rakhshi Asl, Mahboobeh Ashrafi, Mahmoud Aminlari · Journal of Food Biochemistry · 2022

Showing 2 of 7 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

74

Page views

0

PDF downloads

34

Outbound clicks

7

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.